BioCentury | Nov 14, 2020
Product Development

Denali holds gains after first human proof of concept for brain delivery tech

Denali this week reported the first clinical proof-of-concept data from its transport vehicle (TV) technology, which shuttles large molecules across the blood-brain barrier, pushing its shares to...
BioCentury | Aug 7, 2020
Deals

Billion-dollar Biogen deal gives Denali fuel to validate CNS delivery platform

With more than $1 billion in upfront money via its biggest deal yet, Denali now has enough firepower to bring its lead program into late-stage testing and validate its CNS delivery technology in the clinic....
BioCentury | May 30, 2020
Tools & Techniques

Denali offers rare peek into the science behind its CNS delivery platform

Denali is lifting the veil on the delivery technology it’s using to transport large molecules into the CNS, detailing a differentiated strategy for hijacking the transferrin receptor. The company revealed features of its large molecule...
BioCentury | Jan 15, 2020
Clinical News

Denali gains on Parkinson’s results as it looks to select a Phase II candidate

Denali reported data Tuesday from pair of Phase I trials that will inform the company’s selection of a Parkinson’s disease candidate to advance to Phase II. Denali Therapeutics Inc. (NASDAQ:DNLI) gained $5.16 (29%) to $22.74...
BioCentury | Jun 4, 2019
Company News

June 4 Company Quick Takes: Lilly's Emgality gets expanded indication; plus Vimizim, Zerbaxa and more

Emgality gets U.S. approval for episodic cluster headaches FDA approved Emgality galcanezumab-gnlm from Eli Lilly and Co. (NYSE:LLY) to treat episodic cluster headache in adults. The anti-CGRP mAb is already approved as a prophylaxis for...
BioCentury | Feb 15, 2019
Clinical News

Sangamo looks to next-gen therapies after reporting first version 'not enough'

Sangamo Therapeutics Inc. (NASDAQ:SGMO) reported interim data from two Phase I/II trials evaluating its in vivo genome editing zinc finger nuclease (ZFN) therapies SB-913 to treat mucopolysaccharidosis II (MPS II, Hunter syndrome) and SB-318 to...
BioCentury | Feb 8, 2019
Clinical News

Sangamo looks to next-gen therapies after reporting first version 'not enough'

Sangamo Therapeutics Inc. (NASDAQ:SGMO) lost $3.71 (31%) to $8.31 Thursday after the company reported interim data from two Phase I/II trials evaluating its in vivo genome editing zinc finger nuclease (ZFN) therapies SB-913 to treat...
BioCentury | Jan 11, 2019
Company News

Canbridge, Green Cross in China deal for MPS II therapy

In the latest deal between Chinese and Korean biopharmas, Canbridge Pharmaceuticals Inc. (Beijing, China) gained exclusive rights in Greater China to commercialize Hunterase (GC1111) from Green Cross Corp. (KSE:006280) to treat mucopolysaccharidosis II (MPS II,...
BioCentury | Jan 8, 2019
Company News

Canbridge, Green Cross in China deal for MPS II therapy

In the latest deal between Chinese and Korean biopharmas, Canbridge Pharmaceuticals Inc. (Beijing, China) gained exclusive rights in Greater China to commercialize Hunterase (GC1111) from Green Cross Corp. (KSE:006280) to treat mucopolysaccharidosis II (MPS II,...
BioCentury | Sep 7, 2018
Clinical News

Target enzyme undetected at week 16 in Sangamo's MPS II gene editing trial

Sangamo Therapeutics Inc. (NASDAQ:SGMO) reported data showing that plasma iduronate 2-sulfatase (IDS) activity was below the level of quantification through 16 weeks in the Phase I/II CHAMPIONS trial evaluating SB-913 to treat mucopolysaccharidosis II (MPS...
Items per page:
1 - 10 of 253